Moleculin Biotech Q2 2023 cash $32.2M; 33% CR/CRi in AML trial Phase 1B

Moleculin Biotech, Inc.

R&D expense $3.9M, G&A expense $2.5M; cash runway into Q3 2024.
Phase 1B/2 Annamycin monotherapy for soft tissue sarcoma: 73% stable disease after 2 cycles.
Phase 1B portion of Annamycin + Cytarabine for AML completed; 33% CR/CRi rate among 6 patients.
European Phase 1 Annamycin AML results published in British Journal of Cancer Research.
Retained Shareholder Intelligence Services to investigate potential naked short selling.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moleculin Biotech, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 11, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and recent operational highlights.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-023158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.